Vimarsana
Biggest News Aggregation in the World

Page 3 - Dig Dis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dig Dis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dig Dis Today - Breaking & Trending Today

U.S. Food and Drug Administration Approves Bristol Myers Squibb's Zeposia® , an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis1 - Vimarsana News

U.S. Food and Drug Administration Approves Bristol Myers Squibb's Zeposia® , an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis1

Zeposia the first and only oral sphingosine 1-phosphate receptor modulator approved for ulcerative colitis 1 represents a new way of treating this chronic immune-mediated disease 2 Zeposia demonstrated significant improvements across all primary and key secondary efficacy endpoints including clinical remission, clinical response, endoscopic improvement and endoscopic-histologic mucosal improvement versus placebo at ...

Content Moderation Case Studies: Copyright Claims On White Noise (2018) - Vimarsana News

Content Moderation Case Studies: Copyright Claims On White Noise (2018)

Fri, Dec 18th 2020 3:38pm — Copia Institute Summary: Every platform hosting user generated content these days is pretty much required (usually by law) to have policies in place to deal with copyright-infringing material. However, not all content on these platforms is covered by copyright, and that can potentially lead to complications, since policies are often built off of the assumption that everything must be covered by some form of copyright. Australia-based music technologist Sebastian Tomczak, who has a PhD in computer generated music, created from scratch a 10 hour “low level white ...

First patients dosed in Phase III trials evaluating Fasenra in hypereosinophilic syndrome, eosinophilic esophagitis and eosinophilic granulomatosis - Vimarsana News

First patients dosed in Phase III trials evaluating Fasenra in hypereosinophilic syndrome, eosinophilic esophagitis and eosinophilic granulomatosis

Search jobs 16-Dec-2020 First patients dosed in Phase III trials evaluating Fasenra in hypereosinophilic syndrome, eosinophilic esophagitis and eosinophilic granulomatosis with polyangiitis New clinical trial also announced for Fasenra in eosinophilic gastritis/eosinophilic gastroenteritis The first patients have been dosed in Fasenra (benralizumab) Phase III trials in three rare eosinophilic diseases: hypereosinophilic syndrome (HES), eosinophilic esophagitis (EoE) and eosinophilic granulomatosis with polyangiitis (EGPA) AstraZeneca will al...